At the news
? BEARISHIMPACT 8/10 8-K filed Apr 16, 2026 at 07:36 ET
Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase, but missed consensus by $0.00. Revenue of $11.16B grew 7.8% YoY. The company lowered full-year 2026 adjusted EPS guidance to $5.38-$5.58 (from $5.55-$5.80) due to $0.20 dilution from the Exact Sciences acquisition. Despite strong growth in Established Pharmaceuticals and Medical Devices, the guidance reduction drives a bearish sentiment.
- First-quarter 2026 adjusted EPS was $1.15, missing consensus of $1.15 by $0.00 but up 6% YoY
- First-quarter 2026 revenue was $11.16B, beating consensus of $11.00B and growing 7.8% YoY
- Full-year 2026 adjusted EPS guidance was lowered to $5.38-$5.58 from $5.55-$5.80 due to $0.20 dilution from the Exact Sciences acquisition
- The company completed the acquisition of Exact Sciences, establishing a new oncology diagnostics business
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access